Thermo Fisher, NUH, and Mirxes Enhance Genomic Testing for Early Cancer Detection in Singapore
Thermo Fisher Scientific, National University Hospital (NUH), and RNA technology company Mirxes have signed a Memorandum of Understanding (MOU) to increase access to affordable, advanced genomic testing for cancer in Singapore. This partnership aims to develop and clinically validate next-generation sequencing (NGS) solutions tailored for the Southeast Asian population, addressing the limited access to rapid NGS testing in the region.
The collaboration leverages NUH’s clinical expertise and the biotechnology advancements of Thermo Fisher and Mirxes. Associate Professor Tan Soo Yong of NUH highlighted the potential of this partnership to refine early detection methods and deliver precise diagnoses and treatments for cancer. Thermo Fisher’s Sho-Wen Yeo highlighted the ability to provide fast NGS results, aiding in precision medicine for better cancer treatment decisions. Mirxes CEO, Dr Zhou Lihan, noted the company’s commitment to precision medicine and their investment in multi-omic and NGS capabilities for early cancer detection.
Related: Breakthrough Discovery of Key Enzyme’s Role in RNA Modification and Cancer
Currently, the NUH Diagnostic Molecular Oncology Centre offers NGS testing for four common cancers and plans to expand access throughout Southeast Asia.
Category: Technology & Devices
Subscribe
If you enjoyed this article, subscribe to receive more just like it.
